Advances in preeclampsia testing

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Clinical Chemistry

Background:

• Preeclampsia is a serious hypertensive disorder causing significant maternal and fetal complications.
• Current diagnostic methods, including hypertension, proteinuria, and liver enzyme tests, lack specificity and sensitivity.
• There is a critical need for reliable biomarkers for early and accurate preeclampsia detection.

Purpose of the Study:

• To review the clinical characteristics and pathogenesis of preeclampsia, focusing on angiogenic factors.
• To examine current clinical practice guidelines and laboratory testing recommendations for preeclampsia diagnosis.
• To evaluate available placental growth factor (PlGF) and soluble FMS like tyrosine kinase 1 (sFlt-1) assays for clinical utility.

Main Methods:

• Review of clinical characteristics of preeclampsia.
• Analysis of the role of angiogenic factors (PlGF, sFlt-1) in preeclampsia pathogenesis.
• Evaluation of clinical practice guidelines for diagnostic criteria.
• Assessment of methodologies, analytical performance, and clinical values of PlGF and sFlt-1 assays.

Main Results:

• Preeclampsia diagnosis relies on non-specific clinical signs and lab tests.
• Angiogenic factors like PlGF and sFlt-1 are implicated in preeclampsia pathogenesis.
• Available PlGF and sFlt-1 assays show varying degrees of analytical performance and clinical utility.

Conclusions:

• Biomarkers such as PlGF and sFlt-1 hold promise for improving preeclampsia diagnosis and management.
• Further research is needed to optimize analytical and clinical aspects of these biomarkers.
• Enhanced diagnostic tools are essential for reducing maternal and fetal morbidity and mortality associated with preeclampsia.